Metal compounds for the treatment of parasitic diseases

The cysteine proteases of the trypanosomatid parasitic protozoa have been validated as targets for chemotherapy of Chagas’ disease and leishmaniasis. Metal complexes of gold, platinum, iridium, palladium, rhodium and osmium have been reported to have activity against a variety of trypanosomatids, but the molecular target of these compounds has not been defined. The activity of gold(III) and palladium(II) cyclometallated complexes, and oxorhenium(V) complexes against mammalian and parasitic cysteine proteases was investigated. All gold(III) complexes (1–6) inhibited cathepsin B with IC50 values in the range of 0.2–1.4 μM. Of the six palladium compounds, aceto[2,6-bis[(butylthio-κS)methyl]phenyl-κC]-, (SP-4-3)-palladium(II) (11) was the most potent inhibitor of cathepsin B with an IC50 of 0.4 μM. A clear structure–activity relationship was observed with the oxorhenium(V) complexes with chloro[2,2′-(thio-κS)bis[ethanethiolato-κS)]] oxorhenium(V) (16) being the most potent inhibitor of cathepsin B with an IC50 of 0.009 μM. Six complexes were further tested against the parasite cysteine proteases, cruzain from T. cruzi, and cpB from L. major; the most potent inhibitors were the two rhenium complexes (2(1H)-pyridinethionato-κS2)[2,6-bis[(mercapto-κS)methyl]pyridine-κN1] oxorhenium(V) (15) and chloro[2,2′-(thio-κS)bis[ethanethiolato-κS)]] oxorhenium(V) (16). The compounds were also evaluated in assays for parasite growth. Two oxorhenium(V) compounds ((p-methoxyphenylthiolato-S)[2,6-bis[(mercapto-κS)methyl]pyridine-κN1] oxorhenium(V) (14) and (methanethiolato)[2,2′-(thio-κS)bis[ethanethiolato-κS)]] oxorhenium (V) (18)) and the palladium compound 11 inhibited T. cruzi intracellular growth, and compound 11 inhibited promastigote growth in three Leishmania species. In conclusion this preliminary data indicates that metal complexes targeted at parasite cysteine proteases show promise for the treatment of both Chagas’ disease and leishmaniasis.